Oppenheimer & CO Inc Iovance Biotherapeutics, Inc. Transaction History
Oppenheimer & CO Inc
- $5.91 Billion
- Q1 2024
A detailed history of Oppenheimer & CO Inc transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 16,625 shares of IOVA stock, worth $133,332. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,625Holding current value
$133,332% of portfolio
0.0%Shares
10 transactions
Others Institutions Holding IOVA
# of Institutions
303Shares Held
221MCall Options Held
3.05MPut Options Held
1.6M-
Vanguard Group Inc Valley Forge, PA24.9MShares$200 Million0.01% of portfolio
-
Mhr Fund Management LLC New York, NY24MShares$192 Million40.86% of portfolio
-
Black Rock Inc. New York, NY19.9MShares$160 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY19.3MShares$155 Million5.99% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.7MShares$93.8 Million2.09% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $1.27B
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...